These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 25965315)

  • 21. Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.
    Zolla-Pazner S; Cohen SS; Boyd D; Kong XP; Seaman M; Nussenzweig M; Klein F; Overbaugh J; Totrov M
    J Virol; 2016 Jan; 90(2):636-49. PubMed ID: 26491157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
    Utachee P; Isarangkura-na-ayuthaya P; Tokunaga K; Ikuta K; Takeda N; Kameoka M
    Retrovirology; 2014 Apr; 11():32. PubMed ID: 24758333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
    Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
    PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
    J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
    Gorny MK; Revesz K; Williams C; Volsky B; Louder MK; Anyangwe CA; Krachmarov C; Kayman SC; Pinter A; Nadas A; Nyambi PN; Mascola JR; Zolla-Pazner S
    J Virol; 2004 Mar; 78(5):2394-404. PubMed ID: 14963135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection.
    Chan KW; Pan R; Costa M; Gorny MK; Wang S; Lu S; Kong XP
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29997214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
    Honnen WJ; Krachmarov C; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
    J Virol; 2007 Feb; 81(3):1424-32. PubMed ID: 17121806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
    Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
    J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.
    Bonsignori M; Hwang KK; Chen X; Tsao CY; Morris L; Gray E; Marshall DJ; Crump JA; Kapiga SH; Sam NE; Sinangil F; Pancera M; Yongping Y; Zhang B; Zhu J; Kwong PD; O'Dell S; Mascola JR; Wu L; Nabel GJ; Phogat S; Seaman MS; Whitesides JF; Moody MA; Kelsoe G; Yang X; Sodroski J; Shaw GM; Montefiori DC; Kepler TB; Tomaras GD; Alam SM; Liao HX; Haynes BF
    J Virol; 2011 Oct; 85(19):9998-10009. PubMed ID: 21795340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site.
    Cheng HD; Grimm SK; Gilman MS; Gwom LC; Sok D; Sundling C; Donofrio G; Karlsson Hedestam GB; Bonsignori M; Haynes BF; Lahey TP; Maro I; von Reyn CF; Gorny MK; Zolla-Pazner S; Walker BD; Alter G; Burton DR; Robb ML; Krebs SJ; Seaman MS; Bailey-Kellogg C; Ackerman ME
    JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
    Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
    Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
    J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.
    Bagley J; Dillon PJ; Rosen C; Robinson J; Sodroski J; Marasco WA
    Mol Immunol; 1994 Oct; 31(15):1149-60. PubMed ID: 7935503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
    Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
    Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
    Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
    J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of antibody repertoires to the CD4 binding site of gp120 of a Chinese HIV-1-infected elite neutralizer, using 454 sequencing and single-cell sorting.
    Li D; Wang Z; Ren L; Zhang J; Feng G; Hong K; Hao Y; Qi Z; Liang H; Shao Y
    Arch Virol; 2016 Apr; 161(4):789-99. PubMed ID: 26671829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
    Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
    J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.
    Pantophlet R; Aguilar-Sino RO; Wrin T; Cavacini LA; Burton DR
    Virology; 2007 Aug; 364(2):441-53. PubMed ID: 17418361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.